Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
about
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60Drugging topoisomerases: lessons and challengesIn vitro human cell line models to predict clinical response to anticancer drugsUsing drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancerUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyNCI-60 whole exome sequencing and pharmacological CellMiner analysesA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesData Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line EncyclopediaDifferential DNA methylation and PM2.5 species in a 450K epigenome-wide association studyThe P-loop region of Schlafen 3 acts within the cytosol to induce differentiation of human Caco-2 intestinal epithelial cells.Correlating chemical sensitivity and basal gene expression reveals mechanism of action.The NCI-60 Methylome and Its Integration into CellMiner.TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.Targeting the DNA repair pathway in Ewing sarcomaInitial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatmentSLFN11 inhibits checkpoint maintenance and homologous recombination repair.DNA helicases involved in DNA repair and their roles in cancerSLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugsLimited but durable changes to cellular gene expression in a model of latent adenovirus infection are reflected in childhood leukemic cell lines.Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatmentThe schlafen family of proteins and their regulation by interferons.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Reproducible pharmacogenomic profiling of cancer cell line panels.Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.The Schlafen family: complex roles in different cell types and virus replication.Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells.DDX54 regulates transcriptome dynamics during DNA damage responseReport on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerInhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors.Global view of a drug-sensitivity gene network.
P2860
Q26826831-30F9006D-9896-4E8D-9AF0-FE21DB6C3837Q27000099-AE4C27F9-2401-4175-8129-BCF7B58441C6Q27000665-DC8F2B29-8EBF-4D3F-A47B-861B9EB39570Q27320602-C2523042-17B2-44F5-A321-846DBF86850DQ28076097-6BDB9801-CE03-4C90-92D7-47D882305654Q28540834-D8F831C6-3D37-45BB-8516-B32059BCC8F0Q28540936-6A12DB50-415C-4260-B936-16C0F4961F66Q28546078-B03F3830-BD24-4348-9038-210B266BB26AQ29248415-8B88007F-B270-4444-8EF8-72BA211CB80CQ30367233-F4B86C67-B6C5-4BAD-B3DD-1DA5D43B0859Q30381469-BF1AC88C-6061-4D9B-BBA0-6B28038653C1Q30490461-7128CF91-DDE8-43CB-9198-AB29A5047B4DQ31126284-DE73277C-7125-4938-B2B6-19A715951722Q33709790-39013B2E-CF94-4016-B4EE-2FF59FAE87ACQ35268479-546A5B01-95B4-4F90-9082-A9B9FFBF6B92Q35283099-2D4BBD6F-3036-402B-872F-8C6DAB629E02Q35684995-0369C763-6458-4E80-9CBE-1CE7D5F2926DQ35829543-11D93439-3DD0-4BAE-B702-6FC91449708BQ35866775-DD1E406E-8834-4D12-BF99-C20F67061A09Q35961508-8282878C-6B28-49BF-AF31-33A86FC76B3BQ36069053-BC7349F3-C030-44AF-B3E0-839F8FFCD3D6Q36363613-E233636C-65AB-4186-AFFB-7CD36DC2A826Q36772043-D686E33A-1FEB-46F5-A9C9-6427E03DB1DBQ37097260-A1923C09-99F9-491C-BBD1-1EA982E449B1Q37665228-81DA4A7A-49FF-40E4-91DE-B9A65F1756A4Q37684589-5E86D8E6-5C75-43ED-86CC-AD85196E39D0Q37702075-051F551E-A609-4311-BF05-68A34CB0A20DQ38097518-8366FFB5-5FB4-4FC5-BB64-26A4ECB22AD8Q38695896-5289F499-20A8-43E8-BAE1-1E358AF800B6Q38770137-83BAF3EF-1737-4C4E-BDBB-415B21AC23FEQ38870768-38A331A6-FA4C-4FFC-8D05-29E0FB393D6AQ39275728-F2C4E663-67C6-40CF-AE31-B6E5ED3920ABQ40336402-46A5D5A7-BB23-487C-B4D6-C7230B9448E7Q41084434-16B73489-2B7A-4B6B-879D-695061D21436Q41199595-43110200-4135-47E0-B95C-16924B1421C6Q42223681-20EC2992-A5CE-4989-A070-8393A439FF20Q47130816-53F2FD3E-1F35-404C-82F2-E954476642CDQ47838297-708CE161-3482-41D8-B39D-B9116923AD06Q49390599-0B238D02-5CDC-4809-B4DD-CCD9E73553F6Q49850476-606E4091-934E-4C94-BD94-3B2C67C8D891
P2860
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@ast
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@en
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@nl
type
label
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@ast
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@en
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@nl
prefLabel
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@ast
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@en
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@nl
P2093
P2860
P50
P3181
P356
P1476
Putative DNA/RNA helicase Schl ...... r cells to DNA-damaging agents
@en
P2093
Elisabetta Leo
James H Doroshow
Marie Regairaz
Yves Pommier
P2860
P304
15030-15035
P3181
P356
10.1073/PNAS.1205943109
P407
P577
2012-08-27T00:00:00Z